🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT05908227
Recruiting Not applicable

Effects of Flow Magnitude on Cardiorespiratory Stability During Nasal High Flow Therapy in Preterm Infants

NCT05908227 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2023-07-01
Last updated
2025-02-21

Condition(s) studied

Respiratory Distress Syndrome

Investigational drug(s) / intervention(s)

NHF highNHF lowNCPAP

NHF high: Nasal high flow therapy 8L/min.

NHF low: Nasal high flow therapy 6L/min.

NCPAP: Nasal continuous positive airway pressure 6 cm H20

Study summary

Premature babies often need help breathing for a longer period of time. Traditionally, this is done with a breathing aid called NCPAP (nasal continuous positive airway pressure). This treatment is safe and effective, but it is very time-consuming and can sometimes have side effects. In the present research project, the investigators want to find out whether another type of breathing aid called NHF (nasal high flow therapy) is just as effective for stable premature babies. The investigators suspect that NHF is just as effective, but easier to use and more comfortable.

Eligibility

Sex
ALL
Min age
23 Weeks
Max age
31 Weeks
Healthy volunteers
No
Inclusion Criteria: Inclusion if all apply. * Preterm infants up to 31+6 weeks GA admitted to the Division of Neonatology at Inselspital Bern, Switzerland or Division of Neonatology at the University Medical Center of the Johannes Gutenberg-University Mainz, Germany (inborn or outborn) * \>2nd day of life (defined as date day) * Stable on NCPAP 6 cm H2O for ≥ 24 hours, defined as: * ≤ 2 apneas with concomitant bradycardias (\<100/min) per hour for the previous 6 hours * FiO2 ≤ 0.3 and not increasing * No significant chest recessions (Silverman Score \< 5) * Respiratory rate ≤ 60/min * No need for intermittent positive pressure ventilation * Parents with an age 18+ years * Written parental informed consent (or other legal representative) Exclusion Criteria: Exclusion if any applies. * Significant fetal anomalies * Primary palliative care * Stable on NCPAP 6 cm H2O according to stability criteria for more than 120 hours

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
University Medical Center of the Johannes Gutenberg-University Mainz Mainz Rhineland-Palatinate Recruiting
Department of Pediatrics, Inselspital Bern Switzerland Recruiting

More Insel Gruppe AG, University Hospital Bern trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05908227 on ClinicalTrials.gov ↗ ← All trials in Germany